Literature DB >> 19597083

Emerging therapies for relapsing multiple sclerosis.

Jeffrey A Cohen1.   

Abstract

Six agents are currently approved by regulatory agencies to treat relapsing multiple sclerosis. Although these agents are effective and generally safe, some patients have continued disease activity or adverse effects. A sizable number of new agents are under investigation currently. This article reviews emerging agents that have shown promise in phase 2 trials.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19597083     DOI： 10.1001/archneurol.2009.104

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


  12 in total

1.  Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.

Authors:  Fabiola Del Santo; Dario Maratea; Valeria Fadda; Sabrina Trippoli; Andrea Messori
Journal:  Eur J Clin Pharmacol       Date:  2011-11-05       Impact factor: 2.953

2.  A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.

Authors:  Elliot M Frohman; Gary Cutter; Gina Remington; Hongjiang Gao; Howard Rossman; Bianca Weinstock-Guttman; Jacqueline E Durfee; Amy Conger; Ellen Carl; Katherine Treadaway; Eric Lindzen; Amber Salter; Teresa C Frohman; Anjali Shah; Angela Bates; Jennifer L Cox; Michael G Dwyer; Olaf Stüve; Benjamin M Greenberg; Michael K Racke; Robert Zivadinov
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

3.  Management of optic neuritis.

Authors:  Vimla Menon; Rohit Saxena; Ruby Misra; Swati Phuljhele
Journal:  Indian J Ophthalmol       Date:  2011 Mar-Apr       Impact factor: 1.848

4.  Cumulative impact of comorbidity on quality of life in MS.

Authors:  R A Marrie; R Horwitz; G Cutter; T Tyry
Journal:  Acta Neurol Scand       Date:  2011-05-26       Impact factor: 3.209

Review 5.  Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges.

Authors:  Paulo Fontoura
Journal:  MAbs       Date:  2010 Nov-Dec       Impact factor: 5.857

6.  Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction.

Authors:  Kiyoshi Kikuchi; Ko-Ichi Kawahara; Hisaaki Uchikado; Naohisa Miyagi; Terukazu Kuramoto; Tomoya Miyagi; Yoko Morimoto; Takashi Ito; Salunya Tancharoen; Naoki Miura; Kazunori Takenouchi; Yoko Oyama; Binita Shrestha; Fumiyo Matsuda; Yoshihiro Yoshida; Shinihiro Arimura; Kentaro Mera; Ko-Ichi Tada; Narimasa Yoshinaga; Ryuichi Maenosono; Yoshiko Ohno; Teruto Hashiguchi; Ikuro Maruyama; Minoru Shigemori
Journal:  Exp Ther Med       Date:  2011-06-07       Impact factor: 2.447

Review 7.  The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: a systematic review.

Authors:  Ruth Ann Marrie; Nadia Reider; Olaf Stuve; Maria Trojano; Per Soelberg Sorensen; Gary R Cutter; Stephen C Reingold; Jeffrey Cohen
Journal:  Mult Scler       Date:  2014-12-23       Impact factor: 6.312

8.  Magnetic resonance imaging of optic nerve.

Authors:  Foram Gala
Journal:  Indian J Radiol Imaging       Date:  2015 Oct-Dec

9.  Astragaloside IV attenuates experimental autoimmune encephalomyelitis of mice by counteracting oxidative stress at multiple levels.

Authors:  Yixin He; Min Du; Yan Gao; Hongshuai Liu; Hongwei Wang; Xiaojun Wu; Zhengtao Wang
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

10.  Inhibitory effects of edaravone in β-amyloid-induced neurotoxicity in rats.

Authors:  Feng He; Yan-Ping Cao; Feng-Yuan Che; Lian-Hong Yang; Song-Hua Xiao; Jun Liu
Journal:  Biomed Res Int       Date:  2014-04-02       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.